Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
500 μg | $380 | 35 days | |
1 mg | $720 | 35 days | |
5 mg | $2,940 | 35 days |
Description | Phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) act synergistically in promoting cancer. Wortmannin is a potent inhibitor of PI3K enzymes, while rapamycin blocks mTOR Complex 1 TORC1. Wortmannin-rapamycin conjugate consists of analogs of 17-hydroxy wortmannin and rapamycin conjugated via a prodrug linker. Hydrolysis of the prodrug linker in vivo releases the inhibitors. The wortmannin-rapamycin conjugate inhibits the growth of HT-29 colon tumors and A498 renal tumors in mice better than rapamycin alone. Also, the conjugate, when given in combination with the VEGF-blocker bevacizumab, produces substantial regression of larger A498 tumors. Finally, the wortmannin-rapamycin conjugate is tolerated better than an equivalent mixture of the inhibitors. |
Molecular Weight | 1599.014 |
Formula | C88H131N3O23 |
Cas No. | 1067892-47-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Solubility Information | Ethanol: 5 mg/mL DMF: 30 mg/mL DMSO: 20 mg/mL |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.